Drug Deal Disclosure Act

This bill would require the Secretary of Health and Human Services to publish, within 30 days, records and agreements relating to drug pricing deals made between federal agencies and drug manufacturers on or after January 20, 2025. These include deals tied to foreign drug prices, direct-to-consumer sales, tariff exemptions, U.S. investment, and other terms, and specifically list agreements with 16 named drug companies. Records could not be withheld for reputational harm or political sensitivity, but proprietary pricing and other legally protected information could be redacted with a written justification published in the Federal Register. The bill also requires a report to Congress on what was released and withheld, and a joint Congressional Budget Office and Government Accountability Office report on the agreements' economic and budgetary effects.

Full text and official record on Congress.gov

Sponsors

• Ron Wyden Democrat sponsor
• 18 cosponsors